Trials / Completed
CompletedNCT03042611
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 460 (actual)
- Sponsor
- Elevar Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivoceranib | Oral tablet |
| DRUG | Placebo | Oral tablet |
Timeline
- Start date
- 2017-03-14
- Primary completion
- 2019-02-15
- Completion
- 2020-09-23
- First posted
- 2017-02-03
- Last updated
- 2022-07-08
- Results posted
- 2022-07-08
Locations
95 sites across 12 countries: United States, France, Germany, Italy, Japan, Poland, Romania, Russia, South Korea, Taiwan, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03042611. Inclusion in this directory is not an endorsement.